<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Olema Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/olema-pharmaceuticals-inc</link>
<description>Latest news and press releases for Olema Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 20:01:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/olema-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a66278dffbe2df10b7f5.webp</url>
<title>Olema Pharmaceuticals Inc</title>
<link>https://6ix.com/company/olema-pharmaceuticals-inc</link>
</image>
<item>
<title>Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting</title>
<link>https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-to-present-initial-clinical-data-for-op-3136-at-the-2026-asco-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-to-present-initial-clinical-data-for-op-3136-at-the-2026-asco-annual-meeting</guid>
<pubDate>Tue, 21 Apr 2026 20:01:00 GMT</pubDate>
<description>SAN FRANCISCO, April 21, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present initial clinical data from the Phase 1 study of OP-3136 in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 29-June 2 in Chicago, Il</description>
</item>
<item>
<title>Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting</title>
<link>https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-announces-preclinical-data-for-palazestrant-and-op-3136-at-the-2026-aacr-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-announces-preclinical-data-for-palazestrant-and-op-3136-at-the-2026-aacr-annual-meeting</guid>
<pubDate>Fri, 17 Apr 2026 20:01:00 GMT</pubDate>
<description>Palazestrant’s mechanism of action confirmed; full recruitment of corepressor protein NCoR1 enables complete antagonism of the estrogen receptorOP-3136, in combination with palazestrant, exhibits synergistic anti-tumor activity in ER+/HER2- breast cancer models driven by suppression of cell-cycle and estrogen receptor-driven oncogenic signalingPalazestrant is currently being evaluated in two Phase 3 clinical trials; OP-3136 is enrolling patients in the ongoing Phase 1 study SAN FRANCISCO, April</description>
</item>
<item>
<title>Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting</title>
<link>https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-to-present-preclinical-data-for-palazestrant-and-op-3136-at-the-2026-aacr-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-to-present-preclinical-data-for-palazestrant-and-op-3136-at-the-2026-aacr-annual-meeting</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>SAN FRANCISCO, March 17, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical</description>
</item>
<item>
<title>Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results</title>
<link>https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-reports-fourth-quarter-and-full-year-2025-financial-and-operating-results</link>
<guid isPermaLink="true">https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-reports-fourth-quarter-and-full-year-2025-financial-and-operating-results</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2-</description>
</item>
<item>
<title>Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-to-present-at-the-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-to-present-at-the-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Thu, 19 Feb 2026 21:30:00 GMT</pubDate>
<description>SAN FRANCISCO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 2:30 p.m. ET. A live webcast and recordi</description>
</item>
<item>
<title>Olema Oncology to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-participate-upcoming-investor-213000800</link>
<guid isPermaLink="true">https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-participate-upcoming-investor-213000800</guid>
<pubDate>Wed, 04 Feb 2026 21:30:00 GMT</pubDate>
<description>SAN FRANCISCO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences: Guggenheim Securities Emerging Outlook: Biotech Summit Date and Time: February 11, 2026 at 10:00 a.m. ET Format: Fireside C</description>
</item>
<item>
<title>Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-reports-inducement-grants-213000307</link>
<guid isPermaLink="true">https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-reports-inducement-grants-213000307</guid>
<pubDate>Tue, 03 Feb 2026 21:30:00 GMT</pubDate>
<description>SAN FRANCISCO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to two new employees to purchase an aggregate of 24,000 shares of the Company's common stock, effective as of February 2, 2026. These awards were approved by the Compe</description>
</item>
<item>
<title>Olema Oncology Announces Departure of Chief Operating and Financial Officer</title>
<link>https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-announces-departure-chief-210100303</link>
<guid isPermaLink="true">https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-announces-departure-chief-210100303</guid>
<pubDate>Fri, 30 Jan 2026 21:01:00 GMT</pubDate>
<description>SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that Shane Kovacs, Chief Operating and Financial Officer, is departing the Company effective January 30, 2026 to pursue new opportunities. Mr. Kovacs will continue in a consulting capacity with Olema throu</description>
</item>
<item>
<title>Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</link>
<guid isPermaLink="true">https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>SAN FRANCISCO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical</description>
</item>
<item>
<title>Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference</title>
<link>https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-participate-8th-annual-evercore-healthcare-conference-2025-11-21</link>
<guid isPermaLink="true">https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-participate-8th-annual-evercore-healthcare-conference-2025-11-21</guid>
<pubDate>Fri, 21 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical</description>
</item>
<item>
<title>Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares</title>
<link>https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-announces-closing-2185-million-public-offering-common-stock-and-full</link>
<guid isPermaLink="true">https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-announces-closing-2185-million-public-offering-common-stock-and-full</guid>
<pubDate>Thu, 20 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN FRANCISCO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical</description>
</item>
<item>
<title>Olema Oncology Announces Pricing of $190.0 Million Public Offering of Common Stock</title>
<link>https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-announces-pricing-1900-million-public-offering-common-stock-2025-11-19</link>
<guid isPermaLink="true">https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-announces-pricing-1900-million-public-offering-common-stock-2025-11-19</guid>
<pubDate>Wed, 19 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN FRANCISCO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical</description>
</item>
<item>
<title>Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-announces-proposed-public-offering-common-stock-and-pre-funded</link>
<guid isPermaLink="true">https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-announces-proposed-public-offering-common-stock-and-pre-funded</guid>
<pubDate>Tue, 18 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN FRANCISCO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical</description>
</item>
<item>
<title>Olema Oncology Reports Third Quarter 2025 Financial and Operating Results</title>
<link>https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-reports-third-quarter-2025-financial-and-operating-results-2025-11-10</link>
<guid isPermaLink="true">https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-reports-third-quarter-2025-financial-and-operating-results-2025-11-10</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>Announced new clinical trial agreement with Pfizer to evaluate palazestrant in combination with atirmociclib in ER+/HER2- metastatic breast cancerInitiated</description>
</item>
<item>
<title>Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025</title>
<link>https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-present-trial-progress-poster-phase-3-opera-02-trial-palazestrant-plus</link>
<guid isPermaLink="true">https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-present-trial-progress-poster-phase-3-opera-02-trial-palazestrant-plus</guid>
<pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
<description>SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical</description>
</item>
<item>
<title>Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025</title>
<link>https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-announces-new-data-phase-1b-2-trial-palazestrant-plus-ribociclib-er</link>
<guid isPermaLink="true">https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-announces-new-data-phase-1b-2-trial-palazestrant-plus-ribociclib-er</guid>
<pubDate>Sat, 18 Oct 2025 04:00:00 GMT</pubDate>
<description>Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups Median PFS was 15.5 months in the 120 mg</description>
</item>
<item>
<title>Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer</title>
<link>https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-announces-new-clinical-trial-agreement-pfizer-combine-palazestrant</link>
<guid isPermaLink="true">https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-announces-new-clinical-trial-agreement-pfizer-combine-palazestrant</guid>
<pubDate>Tue, 02 Sep 2025 04:00:00 GMT</pubDate>
<description>Study to explore the palazestrant-atirmociclib combination in approximately 35 patients with initiation anticipated in H2 2025 Results to inform potential</description>
</item>
<item>
<title>Olema Oncology Reports Second Quarter 2025 Financial and Operating Results</title>
<link>https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-reports-second-quarter-2025-financial-and-operating-results-2025-08-11</link>
<guid isPermaLink="true">https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-reports-second-quarter-2025-financial-and-operating-results-2025-08-11</guid>
<pubDate>Mon, 11 Aug 2025 04:00:00 GMT</pubDate>
<description>Selected 90 mg once-daily palazestrant for Part 2 of the OPERA-01 Phase 3 monotherapy trial and for the OPERA-02 Phase 3 trial in combination with</description>
</item>
<item>
<title>Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting</title>
<link>https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-announces-palazestrant-dose-selection-and-trial-progress-poster-asco</link>
<guid isPermaLink="true">https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-announces-palazestrant-dose-selection-and-trial-progress-poster-asco</guid>
<pubDate>Wed, 28 May 2025 04:00:00 GMT</pubDate>
<description>90 mg once-daily palazestrant dose selected for Part 2 of the Phase 3 OPERA-01 monotherapy trial and for the Phase 3 OPERA-02 combination trial with</description>
</item>
<item>
<title>Olema Oncology Reports First Quarter 2025 Financial and Operating Results</title>
<link>https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-reports-first-quarter-2025-financial-and-operating-results-2025-05-13</link>
<guid isPermaLink="true">https://6ix.com/company/olema-pharmaceuticals-inc/news/olema-oncology-reports-first-quarter-2025-financial-and-operating-results-2025-05-13</guid>
<pubDate>Tue, 13 May 2025 04:00:00 GMT</pubDate>
<description>Pivotal Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in frontline metastatic breast cancer on track for initiation in 2025, supported</description>
</item>
</channel>
</rss>